Abstract.The relationship between quantitative Plasmodium falciparum or P. vivax parasitemia and clinical illness has not been defined in Pakistan or in other areas where malaria transmission is not highly endemic. Standardized questionnaires were given to and physical examinations and parasitologic tests were performed in 8,941 subjects seen in outpatient clinics in 4 villages for 13 consecutive months in the Punjab region of Pakistan. The results, based on multivariable analysis, showed that a clinical diagnosis of malaria, a history of fever, rigors, headache, myalgia, elevated temperature, and a palpable spleen among children were all strongly associated with the presence and density of P. falciparum or P. vivax malaria in a monotonic dose-response fashion. The malaria attributable fraction of a clinical diagnosis of malaria, and the same symptoms and signs also increased with increasing P. falciparum and, to a lesser extent, P. vivax, parasitemia. Unlike in sub-Saharan Africa, clinical illness due to malaria often occurs in the Punjab among adolescents and adults and in patients with parasite densities less than 1,000/l. Clinical guidelines based upon parasitemia and symptomatology must be adjusted according to the intensity of transmission and be specific for each geographic area.
Morbidity and mortality have been strongly linked toPlasmodium falciparum parasite density and guidelines have been introduced for etiologic classification of febrile illnesses and for therapeutic regimens based upon density of parasites in the blood. While P. falciparum is the predominant species in sub-Saharan Africa, where most of the studies comparing clinical illness with intensity of infection have been conducted, 1-6 malaria in southern Asia and many other endemic areas is caused by both P. falciparum and P. vivax and is characterized by a much lower sporozoite inoculation rate. The relationship between parasite density and clinical illness in such an environment has not been defined as it has been in Africa. Also, the impact of increasing P. vivax parasite density on clinical disease has not been studied as rigorously as has P. falciparum.